Skip to main content
View the latest BOT/BAL presentation from ESMO-GI

Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors

Oct 17, 2025
,
Gordon et al.
ESMO
Colorcectal
Pan Tumor
View Publication
All Molecules
This is some text inside of a div block.
All Conferences
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Clinical Trials
Clear all filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Zalifrelimab (CTLA-4 Antagonist)

Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution.

Other Articles & Publications
Journal for ImmunoTherapy of Cancer
June 2, 2022
,
Florou, et al.
No items found.
Read Now
Download Now
View Article
Zalifrelimab (CTLA-4 Antagonist)

Toxicological and Pharmacological Assessment of AGEN1884, a Novel Human IgG1 anti-CTLA-4 Antibody.

Other Articles & Publications
PLOS
June 2, 2022
,
Gombos, et al.
No items found.
Read Now
Download Now
View Article
No items found.

Mutation-Derived Neoantigens for Cancer Immunotherapy.

Other Articles & Publications
Frontiers in Immunology
June 2, 2022
,
Castle, et al.
No items found.
Read Now
Download Now
View Article
Zalifrelimab (CTLA-4 Antagonist)

Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates.

SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Gombos, et al.
No items found.
Read Now
Download Now
View Poster
Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
Our Science
Pipeline
Publications
Clinical Trials
Immunotherapy
About BOT + BAL
Company
Our History
Our Team
Careers
Partners
Access
Patient Access
Contact Medical Affairs
Resources
Press Releases
In the News
Patient Resources
FAQs
Investors
Investor Overview
Events
Financial Information
Opt-out preferencesCookie PolicyTerms and Conditions of UsePrivacy PolicyCommunity GuidelinesAccess to Investigational Medicines PolicyReport Adverse EventInvestor Portal
© 2025 Agenus Inc. All rights reserved.